Literature DB >> 29599280

Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Daniel Bernstein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29599280      PMCID： PMC5997269          DOI： 10.1161/CIRCRESAHA.118.312921

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  14 in total

1.  The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Authors:  Lynda M Vrooman; Donna S Neuberg; Kristen E Stevenson; Barbara L Asselin; Uma H Athale; Luis Clavell; Peter D Cole; Kara M Kelly; Eric C Larsen; Caroline Laverdière; Bruno Michon; Marshall Schorin; Cindy L Schwartz; Harvey J Cohen; Steven E Lipshultz; Lewis B Silverman; Stephen E Sallan
Journal:  Eur J Cancer       Date:  2011-04-20       Impact factor: 9.162

2.  The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.

Authors:  Shiwei Deng; Tiandong Yan; Teodora Nikolova; Dominik Fuhrmann; Andrea Nemecek; Ute Gödtel-Armbrust; Bernd Kaina; Leszek Wojnowski
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

4.  Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

Authors:  Eric J Chow; Barbara L Asselin; Cindy L Schwartz; David R Doody; Wendy M Leisenring; Sanjeev Aggarwal; K Scott Baker; Smita Bhatia; Louis S Constine; David R Freyer; Steven E Lipshultz; Saro H Armenian
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

Authors:  Hyoung Soo Choi; Eun Sil Park; Hyoung Jin Kang; Hee Young Shin; Chung Il Noh; Yong Soo Yun; Hyo Seop Ahn; Jung Yun Choi
Journal:  J Korean Med Sci       Date:  2010-08-12       Impact factor: 2.153

6.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Authors:  Barbara L Asselin; Meenakshi Devidas; Lu Chen; Vivian I Franco; Jeanette Pullen; Michael J Borowitz; Robert E Hutchison; Yaddanapudi Ravindranath; Saro H Armenian; Bruce M Camitta; Steven E Lipshultz
Journal:  J Clin Oncol       Date:  2015-12-23       Impact factor: 44.544

7.  Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.

Authors:  Alix E Seif; Dana M Walker; Yimei Li; Yuan-Shung V Huang; Marko Kavcic; Kari Torp; Rochelle Bagatell; Brian T Fisher; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2014-03-26       Impact factor: 3.167

8.  Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?

Authors:  Daniel Bernstein
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

Review 9.  Cardioprotective interventions for cancer patients receiving anthracyclines.

Authors:  Elvira C van Dalen; Huib N Caron; Heather O Dickinson; Leontien Cm Kremer
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

10.  A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330
View more
  2 in total

1.  A photochemical-responsive nanoparticle boosts doxorubicin uptake to suppress breast cancer cell proliferation by apoptosis.

Authors:  Ying Zhang; Kaiting Li; Xiaoyu Han; Qing Chen; Lan Shao; Dingqun Bai
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 2.  Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.

Authors:  Neha Bansal; M Jacob Adams; Sarju Ganatra; Steven D Colan; Sanjeev Aggarwal; Rudolf Steiner; Shahnawaz Amdani; Emma R Lipshultz; Steven E Lipshultz
Journal:  Cardiooncology       Date:  2019-12-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.